Published in Journal of Clinical Investigation · View the paper (DOI)
A CHOP-led research study found that B cell activating factor (BAFF) levels are elevated in patients resistant to coagulation protein therapy, suggesting a potential target for new treatments. Anti-BAFF therapies combined with immune tolerance therapies may tame the immune response in some patients with severe hemophilia A.
Coverage from 2 institutions